# Clinical Trial Landscape: 05_melanoma_braf_v600e

*Generated: 2026-01-05 06:56:57*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 11

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 20 | ████ 20.0% |
| Phase 1/Phase 2 | 19 | ███ 19.0% |
| Unknown | 18 | ███ 18.0% |
| Phase 1 | 15 | ███ 15.0% |
| Phase 3 | 11 | ██ 11.0% |
| Not Applicable | 9 | █ 9.0% |
| Early Phase 1 | 5 | █ 5.0% |
| Phase 2/Phase 3 | 3 |  3.0% |

## Status Distribution

- **Recruiting**: 94 (94.0%)
- **Not yet recruiting**: 5 (5.0%)
- **Enrolling by invitation**: 1 (1.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 6 |
| Dana-Farber Cancer Institute | 4 |
| SWOG Cancer Research Network | 3 |
| M.D. Anderson Cancer Center | 3 |
| Merck Sharp & Dohme LLC | 2 |
| Massachusetts General Hospital | 2 |
| Yana Najjar | 2 |
| University of California, San Francisco | 2 |
| NRG Oncology | 2 |
| University of Utah | 2 |
| Mayo Clinic | 2 |
| Eastern Cooperative Oncology Group | 2 |
| University of Louisville | 1 |
| University of Arkansas | 1 |
| University of Nebraska | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Nivolumab | 13 |
| Biospecimen Collection | 12 |
| Pembrolizumab | 9 |
| Computed Tomography | 9 |
| Magnetic Resonance Imaging | 8 |
| Ipilimumab | 7 |
| Questionnaire Administration | 6 |
| Echocardiography Test | 4 |
| Tildrakizumab | 4 |
| Placebo | 4 |
| Multigated Acquisition Scan | 3 |
| Quality-of-Life Assessment | 3 |
| Trametinib | 3 |
| Cyclophosphamide | 3 |
| Cemiplimab | 3 |
| Docetaxel | 3 |
| Cetuximab | 3 |
| Vemurafenib | 2 |
| Sunitinib | 2 |
| Cabozantinib | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Australia | 16 |
| Canada | 13 |
| France | 10 |
| Italy | 10 |
| Spain | 10 |
| Germany | 9 |
| United Kingdom | 9 |
| Israel | 7 |
| Brazil | 6 |
| Netherlands | 6 |
| Puerto Rico | 6 |
| South Korea | 5 |
| Sweden | 5 |
| New Zealand | 5 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| BRAF V600E | manual | 1.0 |
| BRAFV600E | manual | 0.9 |
| BRAF-V600E | manual | 0.9 |
| melanoma | manual | 1.0 |
| BRAF V600E melanoma | manual | 1.0 |
| BRAF V600E cutaneous melanoma | llm | 0.9 |
| BRAF V600E metastatic melanoma | llm | 0.9 |
| cutaneous melanoma | llm | 0.8 |
| metastatic melanoma | llm | 0.8 |
| BRAF V600E mutant | llm | 0.9 |
| BRAF V600E mutation | llm | 0.9 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07068074](https://clinicaltrials.gov/study/NCT07068074) | Phase 3 | Not yet recruiting | Eastern Cooperative ... | A Randomized Phase III Study of Man... |
| [NCT06708455](https://clinicaltrials.gov/study/NCT06708455) | Phase 2 | Not yet recruiting | Rapa Therapeutics LL... | Phase 2 Trial of Autologous Rapamyc... |
| [NCT07040280](https://clinicaltrials.gov/study/NCT07040280) | Phase 2 | Not yet recruiting | Eastern Cooperative ... | A Phase II Double-Blind Trial of Su... |
| [NCT06626516](https://clinicaltrials.gov/study/NCT06626516) | Phase 1/Phase 2 | Recruiting | Thomas Jefferson Uni... | A Phase I/II Study of Tebentafusp-t... |
| [NCT04119024](https://clinicaltrials.gov/study/NCT04119024) | Phase 1 | Recruiting | Anusha Kalbasi | Phase I Dose Escalation Study of Sy... |
| [NCT06814496](https://clinicaltrials.gov/study/NCT06814496) | Phase 1/Phase 2 | Recruiting | University of Arizon... | RAdiation comBined With BIspecific ... |
| [NCT07070232](https://clinicaltrials.gov/study/NCT07070232) | Phase 1/Phase 2 | Recruiting | BioNTech SE | A Phase I/II, Open-label, Adaptive ... |
| [NCT06919809](https://clinicaltrials.gov/study/NCT06919809) | Not Applicable | Recruiting | McGuire Institute | Efficacy and Safety of X A-DERM™ Mi... |
| [NCT06946225](https://clinicaltrials.gov/study/NCT06946225) | Phase 1 | Recruiting | Immatics US, Inc. | A First-in-human, Open-label Trial ... |
| [NCT06902376](https://clinicaltrials.gov/study/NCT06902376) | Phase 1 | Recruiting | UNC Lineberger Compr... | NEO-COMBAT XL: Neoadjuvant and Main... |
| [NCT06697301](https://clinicaltrials.gov/study/NCT06697301) | Phase 2/Phase 3 | Recruiting | Eikon Therapeutics | A Multicenter, Randomized, Double-B... |
| [NCT06975293](https://clinicaltrials.gov/study/NCT06975293) | Phase 1/Phase 2 | Recruiting | STORM Therapeutics L... | Open-label, Non-randomized, Multi-c... |
| [NCT06683755](https://clinicaltrials.gov/study/NCT06683755) | Phase 1/Phase 2 | Not yet recruiting | M.D. Anderson Cancer... | Phase I/IIa Dose Finding Study of T... |
| [NCT06745024](https://clinicaltrials.gov/study/NCT06745024) | Phase 3 | Recruiting | NRG Oncology | Radiation Therapy for High-Risk Asy... |
| [NCT06610682](https://clinicaltrials.gov/study/NCT06610682) | Early Phase 1 | Recruiting | Sidney Kimmel Compre... | Feasibility of CSF (Cerebrospinal F... |
| [NCT06712875](https://clinicaltrials.gov/study/NCT06712875) | Phase 1/Phase 2 | Recruiting | Ann & Robert H Lurie... | A Pilot Study Evaluating the Toxici... |
| [NCT06488365](https://clinicaltrials.gov/study/NCT06488365) | Not Applicable | Recruiting | Cytoastra | In Vivo Liquid Biopsy for Early Det... |
| [NCT06418204](https://clinicaltrials.gov/study/NCT06418204) | N/A | Recruiting | Wake Forest Universi... | Complementary Options for Symptom M... |
| [NCT06771544](https://clinicaltrials.gov/study/NCT06771544) | Phase 2 | Recruiting | University of Califo... | Metronomic Cyclophosphamide With Pe... |
| [NCT06608511](https://clinicaltrials.gov/study/NCT06608511) | N/A | Recruiting | University of Wiscon... | Liquid Biomarker Study in Melanoma ... |
| [NCT06673095](https://clinicaltrials.gov/study/NCT06673095) | Not Applicable | Recruiting | OHSU Knight Cancer I... | ICEMAN (Intelligent Choice of Excis... |
| [NCT06599619](https://clinicaltrials.gov/study/NCT06599619) | N/A | Recruiting | John Kirkwood | A Study of the Effects of Anti-PD1 ... |
| [NCT06666790](https://clinicaltrials.gov/study/NCT06666790) | Not Applicable | Recruiting | DermaSensor, Inc. | DermaSensor Postmarket Surveillance... |
| [NCT06190951](https://clinicaltrials.gov/study/NCT06190951) | Phase 2 | Recruiting | Regeneron Pharmaceut... | A Phase 2 Peri-operative Trial of F... |
| [NCT06475989](https://clinicaltrials.gov/study/NCT06475989) | Phase 3 | Recruiting | ECOG-ACRIN Cancer Re... | A Randomized Phase III Study of BRA... |
| [NCT06440850](https://clinicaltrials.gov/study/NCT06440850) | Phase 2 | Recruiting | City of Hope Medical... | A Pilot Clinical Trial of Vemurafen... |
| [NCT06582745](https://clinicaltrials.gov/study/NCT06582745) | Phase 2 | Recruiting | Cook Children's Heal... | Targeted Approach to Langerhans Cel... |
| [NCT06102902](https://clinicaltrials.gov/study/NCT06102902) | Phase 1 | Recruiting | National Cancer Inst... | A Phase 1 Study of ZEN003694 (ZEN-3... |
| [NCT06402201](https://clinicaltrials.gov/study/NCT06402201) | Phase 1 | Recruiting | CDR-Life AG | Phase 1, First-in-Human Study to As... |
| [NCT06249048](https://clinicaltrials.gov/study/NCT06249048) | Phase 1/Phase 2 | Recruiting | Strand Therapeutics ... | A Phase 1/2, Open-label, Multi-cent... |
| [NCT06265285](https://clinicaltrials.gov/study/NCT06265285) | Phase 2 | Recruiting | Mayo Clinic | Pilot Single-Arm, Pragmatic Trial o... |
| [NCT06326411](https://clinicaltrials.gov/study/NCT06326411) | Phase 1 | Recruiting | Nested Therapeutics,... | A Phase I, Open Label Single-arm Tw... |
| [NCT06439979](https://clinicaltrials.gov/study/NCT06439979) | Not Applicable | Recruiting | University of Utah | Rural Adult and Youth Sun Protectio... |
| [NCT05828069](https://clinicaltrials.gov/study/NCT05828069) | Phase 2 | Recruiting | National Cancer Inst... | Phase 2 Study of Tovorafenib (DAY10... |
| [NCT06194929](https://clinicaltrials.gov/study/NCT06194929) | Phase 1/Phase 2 | Recruiting | University of Utah | Phase 1b/2 Trial of Defactinib and ... |
| [NCT06216938](https://clinicaltrials.gov/study/NCT06216938) | Early Phase 1 | Recruiting | Yana Najjar | Phase I Pilot Study of RP1 in Prima... |
| [NCT06011785](https://clinicaltrials.gov/study/NCT06011785) | Early Phase 1 | Not yet recruiting | HOHM Foundation | Using Silica 12CH to Mitigate the E... |
| [NCT05868629](https://clinicaltrials.gov/study/NCT05868629) | N/A | Recruiting | Novartis Pharmaceuti... | Clinical Study To Further Evaluate ... |
| [NCT06108479](https://clinicaltrials.gov/study/NCT06108479) | Phase 1 | Recruiting | Dragonfly Therapeuti... | A Phase I/Ib, First-In-Human, Multi... |
| [NCT05844982](https://clinicaltrials.gov/study/NCT05844982) | Phase 3 | Recruiting | Jaeb Center for Heal... | A Trial Evaluating Intravitreal Far... |
| [NCT06074588](https://clinicaltrials.gov/study/NCT06074588) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Randomized, Open-label, Phase 3 S... |
| [NCT06090266](https://clinicaltrials.gov/study/NCT06090266) | Phase 1/Phase 2 | Recruiting | OncoResponse, Inc. | A Phase 1/2 Study of OR502 Alone an... |
| [NCT05779423](https://clinicaltrials.gov/study/NCT05779423) | Phase 2 | Recruiting | Massachusetts Genera... | A Phase II Study of Core Needle Bio... |
| [NCT05929768](https://clinicaltrials.gov/study/NCT05929768) | Phase 3 | Recruiting | SWOG Cancer Research... | Shorter Anthracycline-Free Chemo Im... |
| [NCT05907954](https://clinicaltrials.gov/study/NCT05907954) | Phase 2 | Recruiting | IDEAYA Biosciences | (Neo)Adjuvant IDE196 (Darovasertib)... |
| [NCT05520099](https://clinicaltrials.gov/study/NCT05520099) | N/A | Recruiting | Elephas | Observational Basket Trial to Colle... |
| [NCT05859074](https://clinicaltrials.gov/study/NCT05859074) | Phase 1 | Recruiting | Memorial Sloan Kette... | A First-In-Human Phase I, Open Labe... |
| [NCT05463796](https://clinicaltrials.gov/study/NCT05463796) | N/A | Recruiting | Dana-Farber Cancer I... | InAdvance: Surveillance, Prevention... |
| [NCT05786924](https://clinicaltrials.gov/study/NCT05786924) | Phase 1/Phase 2 | Recruiting | Institut de Recherch... | A Phase 1/2, Open-label Study of Or... |
| [NCT05746897](https://clinicaltrials.gov/study/NCT05746897) | Phase 1 | Recruiting | Hefei TG ImmunoPharm... | A Phase 1 Study to Investigate the ... |

*... and 50 more trials (see trials.csv for full list)*
